Meningococcal Vaccines: Current Status and Emerging Strategies

causes most cases of bacterial meningitis. Meningococcal meningitis is a public health burden to both developed and developing countries throughout the world. There are a number of vaccines (polysaccharide-based, glycoconjugate, protein-based and combined conjugate vaccines) that are approved to tar...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2018-02, Vol.6 (1), p.12
Main Authors: McCarthy, Pumtiwitt C, Sharyan, Abeer, Sheikhi Moghaddam, Laleh
Format: Article
Language:English
Subjects:
Combined vaccines
Developing countries
glycoconjugate vaccines
Immunization
LDCs
Meningitis
Neisseria meningitidis
Production methods
protein-based vaccines
Public health
Review
Vaccine development
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:causes most cases of bacterial meningitis. Meningococcal meningitis is a public health burden to both developed and developing countries throughout the world. There are a number of vaccines (polysaccharide-based, glycoconjugate, protein-based and combined conjugate vaccines) that are approved to target five of the six disease-causing serogroups of the pathogen. Immunization strategies have been effective at helping to decrease the global incidence of meningococcal meningitis. Researchers continue to enhance these efforts through discovery of new antigen targets that may lead to a broadly protective vaccine and development of new methods of homogenous vaccine production. This review describes current meningococcal vaccines and discusses some recent research discoveries that may transform vaccine development against in the future.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines6010012